November 17, 2020

Dermavant Named One of Fortune® Magazine’s 2020 “100 Best Small and Medium Companies to Work For”

LONG BEACH, Calif., and BASEL, Switzerland, November 17, 2020—Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today announced the company has made its debut on Fortune’s list of “100 Best Small and Medium Companies to Work For.”

“We are honored to be included on Fortune’s prestigious list of best companies to work for, chosen from a pool of over 1,000 small and medium companies,” said Todd Zavodnick, Chief Executive Officer of Dermavant. “Investing in our employees and ensuring our values resonate throughout our working environment have been paramount for us as a young biotech startup. We strive to make Dermavant a satisfying and rewarding place to work by living these values and providing our hard-working, dedicated employees with the support and motivation they need as we drive the company forward. This is especially important given the unprecedented challenges posed by the current pandemic, which makes this recognition especially welcome.”

To determine the 2020 Best Small Workplaces list and the 2020 Best Medium Workplaces list, Great Place to Work®, the global authority on workplace culture, analyzed confidential survey feedback representing more than 189,000 employees working in small and medium-sized businesses in the United States. Employees responded to over 60 survey questions describing the extent to which their companies create an experience of trust and the ability to reach full potential as part of the team, regardless of role.

About Dermavant

Dermavant Sciences, a subsidiary of Roivant Sciences, is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology. Dermavant’s focus is to develop therapies that have the potential to address high unmet medical needs while driving greater efficiency in research and clinical development. The company’s robust medical dermatology pipeline includes both late-stage and early-development product candidates that target specific unmet needs in two of the largest growing immuno-dermatology markets, psoriasis and atopic dermatitis, as well as other large markets, including vitiligo, primary focal hyperhidrosis, and acne. Dermavant is developing its lead product candidate, tapinarof (DMVT-505), as a novel therapeutic aryl hydrocarbon receptor modulating agent (TAMA) topical cream for the treatment of plaque psoriasis and atopic dermatitis, which affect approximately 8 million and 27 million people in the United States, respectively. The company reported positive Phase 3 results for tapinarof cream in adult patients with plaque psoriasis. For more information, please visit, and follow us on Twitter (@dermavant) and LinkedIn (Dermavant Sciences).

©2020 FORTUNE Media IP Limited. All rights reserved. Used under license.